ScoreWhy is Balaxi Pharmaceuticals Ltd ?
1
Weak Long Term Fundamental Strength with a -27.00% CAGR growth in Operating Profits
2
Negative results in Mar 26
- PAT(9M) At Rs 1.13 cr has Grown at -93.92%
- CASH AND CASH EQUIVALENTS(HY) Lowest at Rs 14.56 cr
- NET SALES(Q) At Rs 70.71 cr has Grown at -7.29%
3
With ROE of 0.6, it has a Very Expensive valuation with a 0.5 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -100.00%, its profits have fallen by -94.3%
4
Below par performance in long term as well as near term
- Along with generating -100.00% returns in the last 1 year, the stock has also underperformed BSE500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Balaxi Pharma for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Balaxi Pharma
-56.05%
-1.18
47.83%
Sensex
-10.0%
-0.78
13.06%
Management Risk
Growth
Capital StructureValuationValuation Key Factors 
Factor
Value
P/E Ratio
95
Industry P/E
Price to Book Value
0.54
EV to EBIT
27.83
EV to EBITDA
20.81
EV to Capital Employed
0.61
EV to Sales
0.66
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
2.18%
ROE (Latest)
0.57%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend1What is working for the Company
NO KEY POSITIVE TRIGGERS
-14What is not working for the Company
PAT(9M)
At Rs 1.13 cr has Grown at -93.92%
CASH AND CASH EQUIVALENTS(HY)
Lowest at Rs 14.56 cr
NET SALES(Q)
At Rs 70.71 cr has Grown at -7.29%
PBDIT(Q)
Lowest at Rs 0.12 cr.
OPERATING PROFIT TO NET SALES (Q)
Lowest at 0.17%
PBT LESS OI(Q)
Lowest at Rs -1.52 cr.
NON-OPERATING INCOME(Q)
is 208.57 % of Profit Before Tax (PBT
Loading Valuation Snapshot...
Here's what is not working for Balaxi Pharma
Profit After Tax (PAT) - Nine Monthly
At Rs 1.13 cr has Grown at -93.92%
Year on Year (YoY)MOJO Watch
Near term PAT trend is very negative
PAT (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs -1.52 cr has Fallen at -113.39%
Year on Year (YoY)MOJO Watch
Near term PBT trend is very negative
PBT less Other Income (Rs Cr)
Net Sales - Quarterly
At Rs 70.71 cr has Grown at -7.29%
Year on Year (YoY)MOJO Watch
Near term sales trend is negative
Net Sales (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Lowest at Rs 0.12 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (Rs Cr)
Operating Profit Margin - Quarterly
Lowest at 0.17%
in the last five quartersMOJO Watch
Company's efficiency has deteriorated
Operating Profit to Sales
Profit Before Tax less Other Income (PBT) - Quarterly
Lowest at Rs -1.52 cr.
in the last five quartersMOJO Watch
Near term PBT trend is negative
PBT less Other Income (Rs Cr)
Non Operating Income - Quarterly
is 208.57 % of Profit Before Tax (PBT)
MOJO Watch
The company's income from non business activities is high; which is not a sustainable business model
Non Operating Income to PBT
Cash and Cash Equivalents - Half Yearly
Lowest at Rs 14.56 cr
in the last six half yearly periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Non Operating Income - Quarterly
Highest at Rs 2.92 cr
in the last five quartersMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating Income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
